View in EDS

Albumin-based delivery systems: Recent advances, challenges, and opportunities

Saved in:
Bibliographic Details
Title: Albumin-based delivery systems: Recent advances, challenges, and opportunities
Authors: Murphy, Gillian, Brayden, David J., Cheung, David L., Liew, Aaron, Fitzgerald, Michael, Pandit, Abhay
Publisher Information: Elsevier
Publication Year: 2025
Collection: National University of Ireland (NUI), Galway: ARAN
Subject Terms: Biomaterials, Albumin, Albumin conjugates, Commercialization, Computational modelling, Albumin nanoparticles, Medical device
Description: Albumin and albumin-based biomaterials have been explored for various applications, including therapeutic delivery, as therapeutic agents, as components of tissue adhesives, and in tissue engineering applications. Albumin has been approved as a nanoparticle containing paclitaxel (Abraxane®), as an albumin-binding peptide (Victoza®), and as a glutaraldehyde-crosslinked tissue adhesive (BioGlue®). Albumin is also approved as a supportive therapy for various conditions, including hypoalbuminemia, sepsis, and acute respiratory distress syndrome (ARDS). However, no other new albumin-based systems in a hydrogel format have been used in the clinic. A review of publicly available clinical trials indicates that no new albumin drug delivery formats are currently in the clinical development pipeline. Although albumin has shown promise as a carrier of therapeutics for various diseases, including diabetes, cancers, and infectious diseases, its potential for treating blood-borne diseases such as HIV and leukemia has not been translated. This review offers a perspective on the use of albumin-based drug delivery systems for a broader range of disease applications, considering the protein properties and a review of the currently approved albumin-based technologies. This review supports ongoing efforts to advance biomedical research and clinical interventions through albumin-based delivery systems. ; This publication has emanated from research conducted with the support of Research Ireland and the European Regional Development Fund (Grant Number 13/RC/2073_P2). This publication has also received funding from Viatris Inc., Galway, Ireland. The authors would like to acknowledge Dr. Raghvendra Bohara for contributing to the manuscript's editorial assessment and proofreading and Maciek Doczyk for contributing to the graphic design of the manuscript figures.
Document Type: article in journal/newspaper
File Description: application/octet-stream
Language: English
Relation: https://hdl.handle.net/10379/18604; https://doi.org/10.13025/29398; https://doi.org/10.1016/j.jconrel.2025.01.035
DOI: 10.13025/29398
DOI: 10.1016/j.jconrel.2025.01.035
Availability: https://hdl.handle.net/10379/18604
https://doi.org/10.13025/29398
https://doi.org/10.1016/j.jconrel.2025.01.035
Rights: Attribution-NonCommercial-NoDerivatives 4.0 International ; http://creativecommons.org/licenses/by-nc-nd/4.0/
Accession Number: edsbas.12B832E
Database: BASE
Description
Abstract:Albumin and albumin-based biomaterials have been explored for various applications, including therapeutic delivery, as therapeutic agents, as components of tissue adhesives, and in tissue engineering applications. Albumin has been approved as a nanoparticle containing paclitaxel (Abraxane®), as an albumin-binding peptide (Victoza®), and as a glutaraldehyde-crosslinked tissue adhesive (BioGlue®). Albumin is also approved as a supportive therapy for various conditions, including hypoalbuminemia, sepsis, and acute respiratory distress syndrome (ARDS). However, no other new albumin-based systems in a hydrogel format have been used in the clinic. A review of publicly available clinical trials indicates that no new albumin drug delivery formats are currently in the clinical development pipeline. Although albumin has shown promise as a carrier of therapeutics for various diseases, including diabetes, cancers, and infectious diseases, its potential for treating blood-borne diseases such as HIV and leukemia has not been translated. This review offers a perspective on the use of albumin-based drug delivery systems for a broader range of disease applications, considering the protein properties and a review of the currently approved albumin-based technologies. This review supports ongoing efforts to advance biomedical research and clinical interventions through albumin-based delivery systems. ; This publication has emanated from research conducted with the support of Research Ireland and the European Regional Development Fund (Grant Number 13/RC/2073_P2). This publication has also received funding from Viatris Inc., Galway, Ireland. The authors would like to acknowledge Dr. Raghvendra Bohara for contributing to the manuscript's editorial assessment and proofreading and Maciek Doczyk for contributing to the graphic design of the manuscript figures.
DOI:10.13025/29398